Navigation Links
ThermoGenesis Announces Filing of 510(k) Application for MarrowXpress
Date:6/4/2008

distributors in Europe and South America.

-- The Thrombin Processing Device(TM) (TPD(TM)) is a sterile blood

processing disposable that prepares activated thrombin from a small

aliquot of plasma in less than 30 minutes. The CE-Marked TPD is

currently being marketed in Europe by Biomet, Inc., subsidiary Biomet

Biologics, Medtronic, Inc. and independent distributors.

This press release contains forward-looking statements, and such statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2008, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2008. A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. ThermoGenesis Announces 510(k) Clearance for AutoXpress(TM) Cord Blood Processing System
2. ThermoGenesis Corp. Reports First Quarter 2008 Results
3. Thermogenesis Announces New Initiative to Address Veterinary Regenerative Medicine
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Heska Corporation (Nasdaq: ... a leading provider of veterinary diagnostic and ... installation of the Company,s new DRI-CHEM® 7000 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, Customers receiving ... multi-patient clinical chemistry analyzer available to the ...
(Date:12/14/2009)... Enough To Wear Pink(TM) (TETWP), the grassroots cowboy ... anniversary at the signature Tough Enough To Wear ... (Wrangler NFR) in Las Vegas. While pink is ... support of the western industry and rodeo fans ... shirts, hats, bracelets and more. ,, Through ...
(Date:12/14/2009)... common CT procedures vary widely and are higher than generally thought, ... study led by University of California, San Francisco (UCSF) ... ... 14, 2009 -- Radiation doses from common CT procedures vary widely ... for cancer, according to a new study led by University of ...
(Date:12/14/2009)... The Hemophilia Federation of America (HFA) ... involving the Teamsters Local 929 and the American ... blood system depends on skilled workers to provide ... distilled into products such as clotting factor for ... ,, The Division of Blood Services at ...
(Date:12/14/2009)... small and shouldn,t worry most users, researcher says , , ... take antidepressants may have a small but statistically significant ... not on the medications, a new study finds. , ... stressed Dr. Jordan W. Smoller, an associate professor of ... a report in the Dec. 14 issue of ...
Breaking Medicine News(10 mins):Health News:Heska Announces Installation of New Chemistry Analyzer 2Health News:Heska Announces Installation of New Chemistry Analyzer 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5Health News:HFA Voices Blood Safety Concerns 2Health News:Antidepressants May Raise Women's Stroke Risk 2Health News:Antidepressants May Raise Women's Stroke Risk 3
... women,s wombs over several assisted reproduction cycles that use ... cheaper than transferring two or more embryos at one ... series of patients who choose to have only one ... (eSET). , The authors of the Finnish study published ...
... Capture, Streamlines Health Records Documentation , ... ... Corporation , a leading developer of healthcare software solutions for ... national leader in enterprise content management and business process automation, ...
... Changes that Hold Health Care Providers Responsible when ... their products are implicated in harm to patients, ... wide contractual and legal protection that renders them ... University of Pennsylvania School of Medicine, ...
... Dealing with a difficult economy and a new ... the Managed Care Executive Group,s (MCEG) annual meeting held in ... Top Ten issues list the group produces each year. ... of strategic positives funded by the federal stimulus package that ...
... Most cervical cancers arose from strains covered by the shot, ... majority of invasive cervical cancers in New Mexico in the ... (HPV16) and HPV type 18 (HPV18), says a new study. ... HPV18-positive cancers were an average of five years younger than ...
... from human papilloma virus type 16 (HPV16) and HPV type ... cancers in New Mexico in the 1980s and 1990s, according ... issue of the Journal of the National Cancer Institute. ... HPV16- or HPV18-positive cancer was 5 years younger than that ...
Other Medicine News:Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 2Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 3Health News:Single embryo transfer is the cheapest and most effective strategy for assisted reproduction 4Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 2Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 3Health News:iMedica and Imagetek Team up to Ease Transition to Paperless Medical Practice 4Health News:Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors? 2Health News:Why Are Healthcare Information Manufacturers Free of All Liability When Their Products Can Result in Medical Errors? 3Health News:Economy and New President Shape This Year's Top Ten Issues Facing Managed Care Executives 2Health News:Economy and New President Shape This Year's Top Ten Issues Facing Managed Care Executives 3Health News:HPV Data May Aid Vaccine's Effectiveness 2Health News:Human papillomavirus genotype distribution in New Mexico cervical cancers 2
(Date:12/14/2009)... 14 Transcept Pharmaceuticals, Inc. (Nasdaq: ... a Notice of Allowance from the United States ... U.S. patent application no. 11/060,641, which covers the ... tartrate sublingual tablet), the lead Transcept product candidate. ... earlier than February 2025. ,, "This is the ...
(Date:12/14/2009)... Dec. 14 In response to an ... 2009, in which the Agency recommended that healthcare ... (SS1) sterile processing system, hospitals throughout the U.S. ... alternatives to that product. According to the FDA, ... SS1 that may affect the safety or the ...
(Date:12/14/2009)... directors of Eli Lilly and Company (NYSE: ... quarter of 2010 of $0.49 a share on outstanding ... March 10, 2010 to shareholders of record at the ... ,, Lilly, a leading innovation-driven corporation, is developing a ... research from its own worldwide laboratories and from collaborations ...
Breaking Medicine Technology:Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 2Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 3Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R) 4ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3New Program to Bring University of Florida Incubator Companies Millions in New Contracts 14804 1New Program to Bring University of Florida Incubator Companies Millions in New Contracts 14804 2New Program to Bring University of Florida Incubator Companies Millions in New Contracts 14804 3New Program to Bring University of Florida Incubator Companies Millions in New Contracts 14804 4SourceMedical Earns Cardinal Health Innovation Award 61207 1SourceMedical Earns Cardinal Health Innovation Award 61207 2The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 1The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 2The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 3The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 4The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 5The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 6The Performance Management Institute of Australia Issues a Warning for Business Leaders 61202 7
... Conference Call Scheduled for 9:00 AM ET ... Dendreon Corporation (Nasdaq:,DNDN) announced today that it ... Phase 3, randomized, double-blind, placebo-controlled IMPACT,(IMmunotherapy for ... trial designed to assess the safety and ...
... Bioabsorbable Stent - Also,Slated for Presentation at Symposium, ... multiple clinical trials of,the world,s first pro-healing stent, ... week at the Transcatheter Cardiovascular,Therapeutics symposium, TCT 2008, ... Ph.D., of the Academic Medical Center in,Amsterdam will ...
Other Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 2Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008 3
... The Plan-Neofluar 63x/1.25 Oil Ph3 ... reflected-light reflection contrast. This method ... brightfield microscopy, such as cells ... a Petri dish. Moreover, this ...
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... redesigned by Nikon allowing the contrast direction ... the objective. That direction, once set, is ... 10x to 40x.,Apodized phase contrast objectives,Nikon's Apodized ... image by reducing internal reflections. The result ...
... Featuring an extra-high transmission rate, especially ... comparable to the CFI plan Achromat ... fluorescence observation and photomicrography. Because ... function as multipurpose objectives for brightfield, ...
Medicine Products: